RETA 3-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Reata Pharmaceuticals (RETA) Investors with Losses to Contact Firm’s Attorneys About Opportunity to Lead Securities Fraud Action
15 févr. 2022 17h30 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud...
RETA 8-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Reata Pharmaceuticals (RETA) Investors with Losses to Contact Firm’s Attorneys Before Feb. 18th Deadline
10 févr. 2022 09h35 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud class...
RETA 13-DAY ALERT: Hagens Berman, National Trial Attorneys, Encourages Reata Pharmaceuticals (RETA) Investors with Losses to Contact Firm’s Attorneys Before Feb. 18th Deadline in Securities Fraud Case
05 févr. 2022 09h46 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Feb. 05, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud class...
RETA INVESTOR NOTICE: Hagens Berman, National Trial Attorneys, Encourages Reata Pharmaceuticals (RETA) Investors with Losses to Contact Firm’s Attorneys, Securities Class Action Pending
31 janv. 2022 12h18 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud...
RETA INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Encourages Reata Pharmaceuticals (RETA) Investors with Losses to Contact Firm’s Attorneys, Securities Class Action Pending
24 janv. 2022 09h40 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud...
RETA INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Encourages Reata Pharmaceuticals (RETA) Investors to Contact Firm’s Attorneys, Securities Class Action Filed
18 janv. 2022 14h01 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud...
RETA DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Reata Pharmaceuticals (RETA) Investors to Contact Firm’s Attorneys, Securities Class Action Pending
13 janv. 2022 14h58 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud...
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Reata Pharmaceuticals (RETA) Investors to Contact Firm’s Attorneys, Deadline Approaching in Securities Class Action
08 janv. 2022 13h05 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 08, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud class...
RETA INVESTOR FRAUD: Hagens Berman, National Trial Attorneys, Encourages Reata Pharmaceuticals, Inc. (RETA) Investors to Contact Firm’s Attorneys, Securities Fraud Class Action Pending
03 janv. 2022 13h42 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud class...
RETA SECURITIES FRAUD: Hagens Berman, National Trial Attorneys, Encourages Reata Pharmaceuticals, Inc. (RETA) Investors to Contact Firm’s Attorneys, Securities Fraud Class Action Pending
28 déc. 2021 09h36 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud class...